Rep Wyden Offers US Medicare Reform Bill

17 March 1997

US Representative Ron Wyden has offered details of his proposedMedicare Modernization and Patient Protection Act of 1997. He stressed the bill's fiscal responsibility; it sets annual spending limits on the Medicare targets set in the Administration proposal.

Unlike the Administration plan, his bill contains a fail-safe mechanism to enforce spending restraints within the program's principal social activity areas. It maintains Part B premiums at current levels and requires prospective payment systems for both home and skilled nursing care; these changes alone should save over $20 billion in five years, he said.

The bill changes the formula for paying capitated programs by de-coupling the Medicare payment system from rises in fee-for-service medicine and creating new constraints on spending in areas where the program has consistently overpaid health plans. It would make the Health Care Financing Administration require competitive bids from capitated programs in those high-pay areas and, where appropriate, in selection and purchase of durable medical equipment and related services.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight